Kornimate/medical-research-clean huggingface dataset:
lung function of asthmatic children by nebulized mgso4

Conditions: Asthma

Summary: asthma is a common chronic respiratory illness which results in frequent wheezing, cough,reduced quality of life. standard treatment for asthma attack includes oxygen therapy, β2-agonists (e.g. albuterol) and inhaled anticholinergics and corticosteroids. although inhaled short-acting β2-agonists (sab) is the initial choice to control acute asthma exacerbation, there are still some asthmatic children unresponsive to this management. the global initiative in national asthma (gina) does not recommend intravenous magnesium sulfate (mgso4) for routine use in asthma exacerbation especially in young children. but intravenous mgso4 can reduce hospital admission rates in certain patients due to several effects e.g relaxation of smooth muscle,blocking acetylcholine. in addition,adding mgso4 to nebulized sab provides greater benefit in severe asthma exacerbation.


Eligibility criteria:
inclusion criteria: * asthmatic children with controlled clinical manifestation exclusion criteria: * fever * history of chronic disease like bronchopulmonary dysplasia or cystic fibrosis * allergic to acetylcholine, albuterol or magnesium * use any bronchodilator agents before the clinic day

Keywords: magnesium sulfate nebulization lung function
study of hcd122 (lucatumumab) and bendamustine combination therapy in cd40+ rituximab-refractory follicular lymphoma

Conditions: Follicular Lymphoma

Summary: this study will assess the safety and efficacy of hcd122 (lucatumumab) when combined with bendamustine in patients with follicular lymphoma.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of follicular lymphoma, according to the revised european american lymphoma/world health organization \[real/who\] classification * documented cd40+ follicular lymphoma * measurable lesion * refractory to rituximab * prior treatment with at least 1 chemotherapeutic regimen * 18 years or older * who performance status grade 0, 1, or 2 * life expectancy \> 3 months * obtained written informed consent exclusion criteria: * grade 3b follicular lymphoma or evidence that the indolent lymphoma has transformed to aggressive lymphoma (i.e. dlbcl) * history of another primary malignancy that is currently clinically significant or currently requires active intervention * prior allogeneic stem cell transplantation * prior anaphylactic or other severe infusion reaction such that the patient is unable to tolerate human immunoglobulin or monoclonal antibody administration * impaired cardiac function or clinically significant cardiac disease * history of acute or chronic pancreatitis, surgery of the pancreas, or any risk factors that may increase the risk of pancreatitis * history of an active infection (viral, bacterial, or fungal) requiring systemic therapy within 28 days before study treatment. * known diagnosis of human immunodeficiency virus (hiv) infection * evidence of previous hepatitis viral infection such as hepatitis b or hepatitis c * ongoing corticosteroid use (\>10 mg/day prednisone or equivalent) * pregnant or nursing (lactating) women other protocol-defined inclusion/exclusion criteria may apply

Keywords: hcd122 lucatumumab cd40 follicular lymphoma non-hodgkin's lymphoma antibody
acute cardiovascular and metabolic effects of exercise training in individuals with insulin resistance

Conditions: Insulin Resistance

Summary: the overall aim of the project is to determine whether or not exercise influences cardiovascular or nervous responses to meal ingestion in individuals with insulin resistance or type 2 diabetes.

participants will undergo a screening procedure, including telephone screening and physical examination, as well as determination of body composition and fitness. participants will be asked to complete 5-10 days of supervised exercise training and will undergo testing to assess cardiovascular and metabolic responses to an oral glucose tolerance test, including muscle sympathetic nerve activity, blood flow, and circulating glucose and insulin concentrations at baseline and following training. in addition, day-to-day variations in blood glucose will also be monitored. the overall aim of the project is to determine whether or not acute exercise training influences postprandial metabolic, vascular or autonomic nervous system responses in individuals with insulin resistance or t2d.

Eligibility criteria:
inclusion criteria: * insulin resistant: diagnosed with pre-diabetes or fasting blood glucose \>/= 100 mg/dl * t2d: diagnosed by primary care physician * bmi: less than 43 kg/m2 * age: 30-65 exclusion criteria: * smoking * insulin use (other than once daily) * underlying conditions that limit ability to exercise safely * recent weight gain or loss (\>5% of body weight in 3 months) * physically active (\>30 min aerobic exercise, 2 d/wk) * recent (\<3 mo) changes in medication use or dose * uncontrolled t2d (hba1c\>10%) * advanced retinopathy or neuropathy * pregnancy

Keywords: insulin resistance type 2 diabetes
effects of obesity on pharmacokinetics of the levonorgestrel emergency contraceptive pill

Conditions: Obesity

Summary: the purpose of this study is to determine the effects of obesity on the pharmacokinetics of the levonorgestrel (lng) only emergency contraceptive (ec) regimen and on markers of ovulation primary hypothesis: 1) obese users of lng-ec have a pharmacokinetic profile that is consistent with a larger volume of distribution of lng. secondary hypothesis: 1. alterations in these pharmacokinetic parameters of the lng-ec regimen in obese women affect the primary mechanism of action, which is inhibition of ovulation. 2. obesity may affect other factors that alter levels of lng, such as sex-hormone binding globulin (shbg) and albumin, which bind lng and potentially lowers the amount of free lng.


Eligibility criteria:
inclusion criteria: * women between ages 18-35 years * regular menstrual cycles (24-35 days) for the past 2 months * ovulatory at defined by midluteal progesterone level \>3 ng/ml (day 18-25) * belongs to one of the following categories: normal weight (bmi = 18.5-24.9 kg/m2), obese (bmi = 30-39.9 kg/m2) or extremely obese (bmi ≥ 40 kg/m2) * participant has no intention of or desire to conceive (e.g., active attempt to become pregnant or in vitro fertilization) for the duration of the study * participant agrees to consistently use an effective method of nonhormonal contraception throughout the duration of study, which could include: condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, non-hormonal intra-uterine devise (iud), or sterilization. * able to give informed consent exclusion criteria: * • known renal or liver disease * known pituitary disorder * known adrenal disorder * known thyroid disorder * use of medication known to alter the cytochrome p450 system * use of depot-medroxyprogesterone acetate in the previous 6 months or any other hormonal contraceptive in the previous 3 months * currently breastfeeding * pregnant * pregnancy in the prior month * known allergy to medication * other specific contraindications to lng ec

Keywords: obesity emergency contraception levonorgestrel emergency contraception
evaluation of the propensity of patients under rhgh to envision a modification of their treatment regimen toward lagh

Conditions: Growth Hormone Deficiency

Summary: daily subcutaneous injections of rhgh can be burdensome for patients, leading to poor adherence and reduced growth outcomes. this has spurred the development of long-acting gh (lagh) analogues that allow for weekly, biweekly, or monthly injections. previous studies on lagh analogues have demonstrated their non-inferiority compared to daily rhgh in terms of increasing growth velocity and improving body composition in children and adults with growth hormone deficiency (ghd), respectively, without significant and unexpected adverse events. since 2020, three molecules have received approval from the food and drug administration (fda) for the treatment of pediatric ghd: lonapegsomatropin, somatrogon, and somapacitan. these lagh analogues may offer better patient acceptance, improved tolerance, and greater therapeutic flexibility. however, these lagh analogues could also be associated with potential clinical issues in terms of therapeutic monitoring, incidence and duration of side effects, and long-term safety due to a non-physiological gh profile. the introduction of these new lagh products will require clinicians to identify optimal candidates for lagh therapy and gain knowledge on monitoring and adjusting treatment.


Eligibility criteria:
inclusion criteria: * belgian and luxembourgish patients currently under rhgh treatment in its various official indications (as per the belgian riziv/inami monitor : growth hormone deficiency, turner syndrome, chronic renal insufficiency, prader-willi syndrome, small for gestational age, noonan syndrome, shox gene deficiency) and included in the belgrow registry * male -female * 0-18 years * free written or e-consent and oral consent exclusion criteria: * no exclusion criteria

Keywords: growth hormone new treatment propensity pediatric
digital intervention postoperative protocol

Conditions: Surgery; Otolaryngologic Disorder; Pain, Postoperative

Summary: postoperative recovery after head and neck surgery is complex, and often requires utilization of narcotic medications. the aim of this study is to evaluate reduction in pain and use of opioid medications through virtual reality (vr) and fitbit wearable activity devices.

enhanced recovery after surgery (eras) protocols were introduced as a method to optimize perioperative patient care. narcotic medications are frequently utilized in postoperative care, but these have risks including sedation or dependence. non-pharmacologic measures for postoperative pain control may help limit the need for opioids in postoperative pain control. early mobilization is also important after surgery, however postoperative mobility is rarely monitored and relies on subjective reports. the investigators will seek to examine the implementation of an eras protocol using vr and fitbit wearable activity devices on postoperative recovery after head and neck surgery. this is a prospective, 4-arm, randomized controlled trial.

Eligibility criteria:
inclusion criteria: * english speaking * 18 to 89 years of age. * planned to undergo major head and neck surgery ohsu with an expected length of stay of two days or more. * ability to understand goals of the study and willingness to sign a written informed consent document. exclusion criteria: * planned postoperative admission to the intensive care unit (icu). * social or psychiatric conditions that may interfere with compliance. * isolation precautions. * reconstruction, incisions, wounds, wound care, or injury that impact the ability to place on the vr headset or wear a fitbit device around the wrist. * history of seizure or epilepsy. * history of vertigo or persistent dizziness. * limitations that impair mobility. * use of a walker or wheelchair at baseline.
a retrospective study of immunotherapy in conversion therapy of unresectable gastric cancer

Conditions: Unresectable Gastric Cancer

Summary: this study was an observational, non-interventional, multicenter retrospective study to evaluate the feasibility and safety of sintilimab combined with chemotherapy (sox or ps) in the clinical practice of unresectable locally advanced or stage iv gastric cancer/gastroesophageal junction carcinoma.


Eligibility criteria:
inclusion criteria: * ages: 18-75 years (concluding 18 and 75 years) * pathologically confirmed gastric/gastroesophageal junction adenocarcinoma * unresectable, locally advanced or limited distant metastasis of iv gastric cancer(ajcc 8th) * meets only ≤2 of the following conditions: highly locally advanced (t4b), or extensive or bulcky lymph nodes; para-aortic lymph node metastasis(mainly 16a2/b1 region); limited liver metastasis(h1); limited peritoneal metastasis(cy1, p1), with or without ovarian metastasis(kukernburg tumor); * untreated(e.g. radiotherapy, chemotherapy, target therapy, immunotherapy, et al.) * at least 1 measurable lesion by recist v1.1 criteria * ecog ps: 0-2 * received sintilimab combined with chemotherapy(sox or ps) at least 1 cycle exclusion criteria: * known her2 positive * patients with incomplete data or other factors affecting the judgment of efficacy and safety

Keywords: unresectable gastric cancer conversion therapy immunotherapy sintilimab
effectiveness of the supportive and palliative care review kit (spark) for cancer patients in the acute hospital

Conditions: Health Services Research

Summary: introduction there is a rising need for palliative care services in singapore due to a rapidly ageing population and an increasing incidence of cancer. current existing resources are inadequate - novel models of care are needed to expand access to palliative care without requiring significantly more specialist palliative care manpower. oncologist-driven referrals to a palliative care consultation service is the norm worldwide, including singapore. this results in variable access to palliative care due to differences in referral practices. palliative care involvement is also often delayed. in this study, the investigators propose to test supportive and palliative care review kit (spark) - a novel integrated model of care in which the palliative care team co-rounds with the medical oncology team. specific aims and hypothesis this study aims to evaluate the impact of spark compared to usual care. the study investigators hypothesize that spark will result in more advanced cancer patients having access to palliative care, and at the same time operate at lower net cost. the study investigators also hypothesize that the improved efficiency of spark will result in shorter hospital length of stay for stage 4 cancer patients. methods a cluster randomized trial with step wedged design will be used to compare spark to usual care. data will be collected on health services utilization and access to palliative care services. net costs will also be compared between spark and usual care. semi-structured interviews with patients and healthcare professionals will be used to explore differences in experiences of healthcare provision between both models of care. importance singapore has a rising prevalence of cancer patients who require palliative care input, but only a minority are able to access it at present. if the spark model of care proves to be a scalable and cost-effective way of expanding access to palliative care, more cancer patients can benefit from palliative care.


Eligibility criteria:
inclusion criteria: * all patients admitted under the care of the medical oncology team in singapore general hospital will be included. exclusion criteria: * patients below 21 years old.

Keywords: palliative care consultation model
a study of the efficacy and safety of relacorilant in patients with endogenous cushing syndrome

Conditions: Cushing Syndrome

Summary: this is a phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (pk) of relacorilant in patients with endogenous cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose tolerance (dm/igt) and/or uncontrolled hypertension (htn).

the primary outcome is the assessment of efficacy of relacorilant treatment based on sustained blood pressure control during the randomized-withdrawal (rw) phase, wherein patients who had achieved the blood pressure response criteria during the open-label (ol) phase are randomized to receive either relacorilant or placebo for 12 weeks. patients in the ol phase will dose-escalate in 100 mg increments to a maximum dose of 400 mg orally once daily. patients will remain on ol treatment until week 22 at which time they will be evaluated for the rw phase based on predefined hyperglycemia and hypertension response criteria. eligible patients will then be randomized to receive either relacorilant or placebo at a 1:1 ratio for 12 weeks. patients who do not meet the criteria for the rw phase will end treatment and may be eligible to roll over into an extension safety study. patients who complete the rw phase of the study may also be eligible to roll over into an extension study.

Eligibility criteria:
inclusion criteria: * has a confirmed diagnosis of endogenous cushing syndrome * meets at least 1 of the following criteria: * has type 2 diabetes mellitus * has impaired glucose tolerance * has hypertension. exclusion criteria: * has non-endogenous source of hypercortisolism * has uncontrolled, clinically significant hypothyroidism or hyperthyroidism * has poorly controlled hypertension * has poorly controlled diabetes mellitus * has severe renal insufficiency.

Keywords: cushing syndrome cushing disease hypercortisolemia cushingoid type 2 diabetes impaired glucose intolerance hypertension adrenocorticotropic hormone primary pigmented nodular adrenal disease moon facies dorsocervical fat pad adrenal adenoma adrenal autonomy cortisol cushing
the effect of implant-supported prosthesis on acoustic voice quality

Conditions: Edentulous Jaw

Summary: the primary aim of this study was to compare the acoustic sound quality of edentulous patients rehabilitated with two-implant overdentures or the all-on-4 concept. the secondary aims were to evaluate the effect of implant and prosthetic success on acoustics.


Eligibility criteria:
inclusion criteria: * no voice disorder or speech therapy * the implant prosthesis was made at least one year ago, delivered to the patient, and continues to be used exclusion criteria: * smoking (\>10 cigarettes/day) or substance use * history of acute or chronic respiratory diseases * overdenture prosthesis on three or 4 implants * history of speech and hearing problems * patients who have lost any implants before the control

Keywords: dental prosthesis, implant-supported speech acoustics
a trial of gemtuzumab ozogamicin (go) in combination with zosuquidar in patients with cd33 positive acute myeloid leukemia

Conditions: Leukemia, Myeloid

Summary: chemotherapy drugs use different ways to stop cancer cells from dividing so they stop growing or die. zosuquidar may help gemtuzumab ozogamicin (go) kill more cancer cells by making cancer cells more sensitive to the drug. it is not known whether gemtuzumab ozogamicin (go) is more effective with or without zosuquidar in treating acute myeloid leukemia.

purpose: phase i: determine the optimal dose and schedule of go and zosuquidar when used in combination. phase ii: determine the complete remission rate (cr+crp)

Eligibility criteria:
inclusion criteria: 1. morphologic evidence of acute myeloid leukemia in first relapse. 2. phase i: 18 years or older, phase ii: 50 years or older exclusion criteria: 1. prior treatment with zosuquidar 2. any investigational agent within 1 month of enrollment and lack of recovery from toxicities secondary to those agents 3. history of stem cell transplant

Keywords: leukemia, myeloid relapse chemotherapy zosuquidar gemtuzumab ozogamicin (go)
89zrtrastuzumab breast imaging with positron emission tomography

Conditions: Breast Cancer

Summary: the main purpose of this study is to see if positron emission tomography (pet-imaging) with 89zr labeled trastuzumab can detect trastuzumab (her2) positive breast cancer.


Eligibility criteria:
inclusion criteria: * female patients 18 years of age or older * cohort 1: her2-positive (defined as 3+) or fish her2:cep17 ratio \> 2 biopsy proven breast cancer * cohort 2: her2-positive (defined as 3+) or fish her2:cep17 ratio \> 2 or her2negative (0 or 1+, 2+ and fish negative) biopsy-proven breast cancer * primary or recurrent/metastatic lesion size ≥ 1.5 cm as determined by imaging studies (ultrasonography, mammography, ct or mri) or physical examination * able to give informed consent * not currently pregnant or nursing: subject must be surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (cessation of menses for more than 1 year), non-lactating, or of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of 89zr-trastuzumab) is negative * patients currently receiving trastuzumab therapy with or without other types of systemic therapy can participate if their disease progresses (development of new lesion(s) or worsening of known lesion(s) based on imaging modalities or physical examination. exclusion criteria: * patients with other invasive malignancies, with the exception of non- melanoma skin cancer, who had (or have) any evidence of the other cancer present within the last 5 years * unable to tolerate 60 min of pet imaging per imaging session

Keywords: trastuzumab
atrial fibrillation and other cardiac arrhythmias and diseases after radiotherapy for breast cancer : watch your heart

Conditions: Breast Cancer; Radiation Toxicity; Atrial Fibrillation; Cardiac Arrhythmia; Cardiac Disease

Summary: the goal of this interventional study is to evaluate the risk of atrial fibrillation (af) and other cardiac arrhythmias and diseases in breast cancer patients treated with radiation therapy (rt). in addition to regular follow-up of patients by the radiation oncologist for 5 years, cardiovascular screening at the end of follow-up, combining the use of a connected watch and a cardiological check-up, could make it possible to identify precisely the types and frequencies of these sometimes asymptomatic, and probably underestimated, cardiac diseases. the main questions it aims to answer are: * to assess the incidence of af and other cardiac arrhythmias and diseases occurring within 5 years after rt * to evaluate absorbed doses in the heart and cardiac substructures (chambers, conduction nodes, coronaries, pulmonary veins) based on auto-segmentation models developped with deep learning algorithms * to investigate whether the risk of af and other cardiac arrhythmias and diseases is associated with cardiac irradiation characterized by these absorbed doses (dose-response relationship) participants will be included between 2023 and 2025, 5 years after their rt: * retrospective data collection will be based on a medical questionnaire designed to identify cardiac pathologies present prior to rt and those having occured in the past, between rt and 5 years post-rt. * cross-sectional data collection will be based on screening for cardiac pathologies using a connected watch worn for 1 month (silent af screening) and a cardiology consultation (including ecg and echocardiography) to identify cardiac pathologies at 5 years post-rt possibly not identified in the retrospective data collection.


Eligibility criteria:
inclusion criteria: * women treated surgically for primary cancer of the left or right breast and for whom adjuvant treatment is rt with irradiation of the breast or chest wall and possibly irradiation of lymph node chains, * adjuvant radiotherapy performed at clinique pasteur between 2018 and 2020, * 5-year post-rt follow-up radiation oncologist consultation performed at clinique pasteur * age ≥ 65 years at the time of the 5-year post-rt follow-up consultation * own a smartphone and able to understand and use digital tools alone and/or with the help of a caregiver ; * patient having consented to connected follow-up, * be affiliated to a social security scheme or equivalent * be willing to participate in the study and have signed the consent form exclusion criteria: * history of cancer before breast cancer rt * recurrence of breast cancer or other cancer treated after breast cancer rt * history of atrial fibrillation prior to breast cancer rt